Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Manage your formulary budget
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Expression of biologically active PDGF analogs in eucaryotic cells|
|Abstract:||Biologically active PDGF analogs expressed in eucaryotic cells are disclosed. The analogs are produced by yeast strains transformed with an extrachromosomal element composed of a strong transcriptional promoter directing the expression of a gene which encodes a protein having substantially the same biological activity as PDGF. Suitable genes include the v-sis gene or a derivative of the v-sis gene of simian sarcoma virus or portions thereof, or the human cDNA gene for PDGF or portions thereof. In particular, DNA sequences encoding polypeptides substantially homologous to the B chain of PDGF are preferred. A secretory signal sequence may be provided upstream of the gene, enabling secretion of the gene product from the host cell. Mitogenic activity is one of the biological activites possessed by these PDGF analogs, making them useful in promoting the growth of mammalian cells.|
|Inventor(s):||Murray; Mark J. (King County, WA), Kelly; James D. (King County, WA)|
|Assignee:||ZymoGenetics, Inc. (Seattle, WA)|
|Filing Date:||Aug 23, 1988|
|Claims:||1. A protein homodimer consisting essentially of human PDGF B-chains, said protein being essentially free of the A-chain of PDGF. |
2. The protein of claim 1 wherein said protein is essentially free of other proteins of mammalian or viral origin.
3. A protein consisting essentially of two disulfide bonded polypeptide chains, each of said chains consisting essentially of the amino acid sequence shown in FIG. 1B, beginning with serine, number 67, and ending with threonine, number 175, said protein being essentially free of other proteins of mammalian of viral origin.
4. A recombinant protein homodimer comprising component polypeptide chains substantially identical to the B-chain of human PDGF, said protein being essentially free of the A-chain of PDGF.
5. The protein of claim 4 wherein said protein is essentially free of other proteins of mammalian or viral origin.
6. A recombinant protein homodimer consisting essentially of component polypeptide chains substantially identical to the B-chain of human PDGF, said protein being essentially free of the A-chain of PDGF.
7. The protein of claim 6 wherein said protein is essentially free of other proteins of mammalian or viral origin.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.